Science news

<<  return



European Society of Cardiology 2014 Congress: This is a new day in heart failure," said Dr Clyde Yancy (Northwestern University, Chicago, IL). "Yancy"s acclamation to heartwirereferred to the seeming knockdown success of the novel drug studied in PARADIGM-HF . It surpassed the classic ACE inhibitor enalapril at diminishing cardiovascular mortality in the convincingly huge trial.